Frequently Asked Questions

What counts as big data in life sciences?

NIST defines big data as extensive datasets, mainly characterized by volume, variety, velocity, or variability, that need a scalable architecture to store, process, and analyze efficiently. The seven factors in this article build on the original three, volume, velocity, and variety, which analyst Doug Laney described in 2001.

 

What is the difference between real-world data and real-world evidence?

The FDA defines real-world data (RWD) as data about patient health status or the delivery of health care that is routinely collected from a variety of sources, such as electronic health records, medical claims, product and disease registries, and digital health technologies. Real-world evidence (RWE) is the clinical evidence about a medical product’s usage and potential benefits or risks that comes from analyzing that data. RWD is the input, and RWE is what you can conclude from it.

 

How does third-party claims data fit into life sciences analytics?

Medical claims are one of the real-world data sources the FDA lists, and life sciences companies can access them through vendors such as IQVIA, Symphony Health, and Veeva Compass Data Suite. Combining claims data from more than one vendor means harmonizing it into a single data model and cleansing, mapping, and validating it first. Conexus onboards and standardizes claims data so it can support dashboards, predictive modeling, patient journey analysis, and real-world evidence work.